581 related articles for article (PubMed ID: 11383324)
21. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
Haas S
Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
[TBL] [Abstract][Full Text] [Related]
22. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
[TBL] [Abstract][Full Text] [Related]
23. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
24. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Harrington RA; Becker RC; Ezekowitz M; Meade TW; O'Connor CM; Vorchheimer DA; Guyatt GH
Chest; 2004 Sep; 126(3 Suppl):513S-548S. PubMed ID: 15383483
[TBL] [Abstract][Full Text] [Related]
25. Low-molecular-weight heparin: an antithrombotic agent whose time has come.
Futterman LG; Lemberg L
Am J Crit Care; 1999 Jan; 8(1):520-3. PubMed ID: 9987551
[TBL] [Abstract][Full Text] [Related]
26. Low-molecular-weight heparins in clinical practice.
Hunt D
South Med J; 1998 Jan; 91(1):2-10. PubMed ID: 9438394
[TBL] [Abstract][Full Text] [Related]
27. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
Husted SE; Nielsen HK
Ugeskr Laeger; 2010 Oct; 172(42):2888-91. PubMed ID: 21040659
[TBL] [Abstract][Full Text] [Related]
28. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
29. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Douketis JD; Berger PB; Dunn AS; Jaffer AK; Spyropoulos AC; Becker RC; Ansell J
Chest; 2008 Jun; 133(6 Suppl):299S-339S. PubMed ID: 18574269
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Kearon C; Akl EA; Comerota AJ; Prandoni P; Bounameaux H; Goldhaber SZ; Nelson ME; Wells PS; Gould MK; Dentali F; Crowther M; Kahn SR
Chest; 2012 Feb; 141(2 Suppl):e419S-e496S. PubMed ID: 22315268
[TBL] [Abstract][Full Text] [Related]
31. Clinical potential of antithrombotic drugs in coronary syndromes.
Turpie AG
Am J Cardiol; 1998 Sep; 82(5B):11L-14L. PubMed ID: 9737474
[TBL] [Abstract][Full Text] [Related]
32. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
33. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Menon V; Harrington RA; Hochman JS; Cannon CP; Goodman SD; Wilcox RG; Schünemann HJ; Ohman EM
Chest; 2004 Sep; 126(3 Suppl):549S-575S. PubMed ID: 15383484
[TBL] [Abstract][Full Text] [Related]
34. [Thrombophilia, preeclampsia and other pregnancy complications].
Vucić N; Frleta M; Petrović D; Ostojić V
Acta Med Croatica; 2009 Oct; 63(4):297-305. PubMed ID: 20034330
[TBL] [Abstract][Full Text] [Related]
35. [Initial treatment of venous thromboembolic events].
Mismetti P; Decousus H; Moulin N
Rev Prat; 2007 Apr; 57(7):751-7. PubMed ID: 17626320
[TBL] [Abstract][Full Text] [Related]
36. [Antithrombotic therapy for ischemic cerebrovascular accident].
Mas JL
Arch Mal Coeur Vaiss; 2002 Nov; 95 Spec No 7():53-7. PubMed ID: 12500606
[TBL] [Abstract][Full Text] [Related]
37. State of the art--a journey through the world of antithrombotic therapy.
Turpie AG
Semin Thromb Hemost; 2002 Aug; 28 Suppl 3():3-11. PubMed ID: 12232817
[TBL] [Abstract][Full Text] [Related]
38. Low molecular weight heparin in unstable coronary artery disease.
Wallentin L
Expert Opin Investig Drugs; 2000 Mar; 9(3):581-92. PubMed ID: 11060697
[TBL] [Abstract][Full Text] [Related]
39. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
Kamphuisen PW; Agnelli G
Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of venous thrombosis in cancer patients: practical aspects].
Laza-Achille M; Desruennes E; Di Palma M
Bull Cancer; 2006 Mar; 93(3):271-81. PubMed ID: 16567314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
